MODIFIED CpG OLIGODEOXYNUCLEOTIDE WITH IMPROVED IMMUNOREGULATORY FUNCTION

A method for treating cancer in a patient comprising:

• a) administering to a patient a structurally modified oligodeoxynucleotide (ODN) having immunoactivity and a CpG motif and consisting of the nucleotide sequence of SEQ ID NO:
• 5, wherein the ODN has a consecutive sequence of 4 deoxyribothymines (dT) at the 3′-terminus of ODN, which is modified by changing the phosphodiester bonds into phosphorothioated bonds;
• b) allowing the composition to increase immunoactivity of splenocytes, macrophages or peripheral blood mononuclear cells thereby treating the cancer.

A method for treating cancer in a patient comprising:

• a) administering to a patient a structurally modified oligodeoxynucleotide (ODN) having immunoactivity and a CpG motif and comprising the nucleotide sequence of SEQ ID NO:
• 5, wherein the ODN has a consecutive sequence of 4 deoxyribothymines (dT) at the 3′-terminus of ODN, which is modified by changing the phosphodiester bonds into phosphorothioated bonds;
• b) allowing the composition to increase immunoactivity of splenocytes, macrophages or peripheral blood mononuclear cells thereby treating the cancer.

A method for increasing immunoactivity of splenocytes, macrophages or peripheral blood mononuclear cells in a patient comprising:

• a) administering to a patient a structurally modified oligodeoxynucleotide (ODN) having immunoactivity and a CpG motif and consisting the nucleotide sequence of SEQ ID NO:
• 5, wherein the ODN has a consecutive sequence of 4 deoxyribothymines (dT) at the 3′-terminus of ODN, which is modified by changing the phosphodiester bonds into phosphorothioated bonds;
• b) allowing the composition to increase immunoactivity of splenocytes, macrophages or peripheral blood mononuclear cells.

A method for increasing immunoactivity of splenocytes, macrophages or peripheral blood mononuclear cells in a patient comprising:

• a) administering to a patient a structurally modified oligodeoxynucleotide (ODN) having immunoactivity and a CpG motif and comprising the nucleotide sequence of SEQ ID NO:
• 5, wherein the ODN has a consecutive sequence of 4 deoxyribothymines (dT) at the 3′-terminus of ODN, which is modified by changing the phosphodiester bonds into phosphorothioated bonds;
• b) allowing the composition to increase immunoactivity of splenocytes, macrophages or peripheral blood mononuclear cells.